Show simple item record

dc.contributor.authorAbou-Alfa, GK
dc.contributor.authorMercade, TM
dc.contributor.authorJavle, M
dc.contributor.authorKelley, RK
dc.contributor.authorLubner, S
dc.contributor.authorAdeva, J
dc.contributor.authorCleary, JM
dc.contributor.authorCatenacci, DV
dc.contributor.authorBorad, MJ
dc.contributor.authorBridgewater, JA
dc.contributor.authorHarris, WP
dc.contributor.authorMurphy, AG
dc.contributor.authorOh, DY
dc.contributor.authorWhisenant, J
dc.contributor.authorWu, B
dc.contributor.authorJiang, L
dc.contributor.authorGliser, C
dc.contributor.authorPandya, SS
dc.contributor.authorValle, Juan W
dc.contributor.authorZhu, AX
dc.date.accessioned2019-12-09T17:23:31Z
dc.date.available2019-12-09T17:23:31Z
dc.date.issued2019en
dc.identifier.citationAbou-Alfa GK, Macarulla Mercade T, Javle M, Kelley RK, Lubner S, Adeva J, et al. LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology. 2019;30(Supplement_5):872.en
dc.identifier.doi10.1093/annonc/mdz394.027en
dc.identifier.urihttp://hdl.handle.net/10541/622597
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz394.027en
dc.titleClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutationen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedicine, Memorial Sloan-Kettering Cancer Center, New York, NYen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T20:22:09Z


Files in this item

Thumbnail
Name:
mdz394.027.pdf
Size:
101.3Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record